Zydus Receives USFDA's Final Approval For Entecavir Tablets

Zydus Cadila has received final approval from the USFDA to market Entecavir tablets in the strengths of 0.5 mg and 1mg.

The drug is used to treatment of Hepatitis B virus infection and will be produced at the group’s formulation manufacturing facility at the Pharma SEZ in Ahmedabad.

The estimated sale of Entecavir tablets is $166.3 million.

The group has now more than 120 approvals and has so far filed over 300 ANDA’s since the commencement of the filing process in FY 2003-04.

Cadila Healthcare Limited is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness Limited, Liva Pharmaceuticals Limited, Biochem Pharmaceutical Industries Limited, Zydus Technologies Limited, German Remedies Limited, Dialforhealth India Limited, etc. 

For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.